Review reveals metabolomics advances for thyroid cancer diagnosis and therapy, highlighting potential biomarkers to reduce unnecessary surgeries.
Thyroid cancer (TC) is one of the most common endocrine malignancies with high incidence and heterogeneity.Its diagnosis mainly relies on ultrasound-guided fine-needle aspiration biopsy,while it still fails to give a definitive diagnosis in 15%-30% of lesions,leading to a large number of unnecessary repeat biopsies and surgical procedures.Metabolomics,as a newly developed discipline,plays a role in the early diagnosis,treatment,and prognosis of TC by detecting differential metabolites in a variety of biological samples,such as tissue and blood,and researching the differential expression of metabolic pathways in TC.This review summarizes the research progress of metabolomics in the last 5 years,aiming to provide a theoretical basis for the screening of diagnostic biomarkers and exploring potential therapeutic targets for TC.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: